Clostridioides difficile, commonly referred to as C. diff, is a highly contagious bacteria that causes diarrhoea. While mild for most people it can trigger life-threatening complications and kills ...

Pfizer's vaccine for Clostridium difficile (C. diff) looks like it may join a growing list of candidates that have been shelved or delayed, after the shot failed to meet its primary objective in a ...

REBYOTA is the first microbiome-based therapy approved for the prevention of recurrent Clostridioides difficile (C. diff) infection (CDI) in individuals 18 years of age and older, following ...

He added, “This works and it works quite well.” Ferring presents new phase 3b safety and effectiveness data for recurrent C. diff patients receiving Rebyota (fecal microbiota, live-jslm ...

The D.C. region’s economy is teetering on the edge ... citing layoffs and other financial strains. When new clients do sign up, they’re increasingly opting for daily or monthly packages ...

Data presented at Digestive Disease Week (DDW) 2025 demonstrated safety and treatment success in patients treated for recurrent C. Diff infection with REBYOTA administered by colonoscopy Data also ...

May 1 (Reuters) - U.S. health agencies said on Thursday they are seeking to develop a universal vaccine technology to target multiple strains of different viruses such as influenza and ...

This is an educational article on women's probiotics, with best-sellers such as Bioma, on essential strains and myths debunked on how probiotics support gut health, vaginal balance, etc. If you're ...

Sixty-four more hospitals had a rate of zero, the lowest rate possible, for C. diff infections compared to CMS’ 2023 list.

The FDA typically selects strains for the updated vaccines in June so they can be ready for distribution by the fall. Experts warn that requiring placebo-controlled trials before clearing new ...